Can an enzyme shield the gut during transplant recovery?

NCT ID NCT04692181

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an oral enzyme called SYN-004 in adults who have received a stem cell transplant and need intravenous antibiotics for fever. The enzyme is designed to break down antibiotics in the gut, protecting the natural bacteria there. Researchers will check safety, whether the enzyme enters the blood, and if it helps prevent infections and improve outcomes. The trial involves 36 participants and is in early phases (1b/2a).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SYN-004 (Ribaxamase), an oral enzyme that breaks down certain antibiotics in the gut

What this could lead to

If it works, SYN-004 could help protect the gut microbiome during antibiotic treatment, potentially reducing infections and improving recovery in stem cell transplant patients.

What could go wrong

This is an early-phase trial with only 36 participants, so results may not apply broadly. The drug might not effectively protect the microbiome or could interfere with antibiotic levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease hematopoietic and lymphoid cell neoplasm myeloproliferative neoplasm Clostridium difficile colitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Washington University

    St Louis, Missouri, 63110, United States